Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities

Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis

(2020) C.R.H. Hedin et al.   Clinical Gastroenterology and Hepatology

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis

(2020) Kris V. Kowdley et al.   JOURNAL OF HEPATOLOGY

The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC

(2019) Michael Trauner et al.   HEPATOLOGY

Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis

(2019) Nobuhiro Nakamoto et al.   Nature Microbiology

Cholangiocyte pathobiology

(2019) Jesus M. Banales et al.   Nature Reviews Gastroenterology & Hepatology

Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis

(2019) Lijun Liao et al.   GUT

Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis

(2019) Jessica R. Allegretti et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

(2019) Kate D. Lynch et al.   Clinical Gastroenterology and Hepatology

Emerging roles of bile acids in mucosal immunity and inflammation

(2019) Mei Lan Chen et al.   Mucosal Immunology

A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection

(2019) Theodore Rokkas et al.   United European Gastroenterology Journal

Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis

(2019) Malte Rühlemann et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

AGA Institute Clinical Practice Update: Surveillance for Hepatobiliary Cancers in Patients with Primary Sclerosing Cholangitis

(2019) Christopher L. Bowlus et al.   Clinical Gastroenterology and Hepatology

Fecal Microbial Transplantation for Diseases Beyond Recurrent Clostridium Difficile Infection

(2019) Geert R. D’Haens et al.   GASTROENTEROLOGY

Alterations of the bile microbiome in primary sclerosing cholangitis

(2019) Timur Liwinski et al.   GUT

Validation, Clinical Utility and Limitations of the Amsterdam-Oxford Model for Primary Sclerosing Cholangitis

(2019) Jorn C. Goet et al.   JOURNAL OF HEPATOLOGY

Pathogenesis, diagnosis and treatment of premalignant and malignant stages of cholangiocarcinoma in primary sclerosing cholangitis

(2019) Marit Maehle Grimsrud et al.   LIVER INTERNATIONAL

Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

(2019) Ayesha Shah et al.   SEMINARS IN LIVER DISEASE

Gut microbiota in PSC : From association to possible causality. Commentary to “Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis” by Nakamoto et al., Nature Microbiology, January 2019

(2019) Sara Lemoinne et al.   Clinics and Research in Hepatology and Gastroenterology

Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis

(2019) Amandeep K. Dhillon et al.   Scientific Reports

Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses

(2019) Sara Vieira-Silva et al.   Nature Microbiology

Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study

(2019) Michael Trauner et al.   Lancet Gastroenterology & Hepatology

The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications

(2019) Jessica R Allegretti et al.   LANCET

Bile acid metabolites control TH17 and Treg cell differentiation

(2019) Saiyu Hang et al.   NATURE

Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease

(2019) Yi Duan et al.   NATURE

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

T cell receptor cross-reactivity between gliadin and bacterial peptides in celiac disease

(2019) Jan Petersen et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease

(2018) B. Christensen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis

(2018) M. J. Nielsen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis

(2018) J. L. Damman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium

(2018) Mario Strazzabosco et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma

(2018) Brian K. Chung et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Colesevelam attenuates cholestatic liver and bile duct injury inMdr2−/−mice by modulating composition, signalling and excretion of faecal bile acids

(2018) Claudia Daniela Fuchs et al.   GUT

Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis

(2018) Cyriel Y. Ponsioen et al.   HEPATOLOGY

Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes in PSC: A Derivation & Validation Study Using Machine Learning

(2018) John E. Eaton et al.   HEPATOLOGY

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

(2018) Scott L. Friedman et al.   HEPATOLOGY

Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis

(2018) Ahmad Hassan Ali et al.   HEPATOLOGY

Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis

(2018) Marion J. Pollheimer et al.   JOURNAL OF HEPATOLOGY

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

(2018) Christophe Corpechot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease

(2018) Andrew J. Muir et al.   HEPATOLOGY

Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis

(2018) Amandeep K Dhillon et al.   LIVER INTERNATIONAL

Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French–Spanish experience

(2018) Sara Lemoinne et al.   Clinics and Research in Hepatology and Gastroenterology

Oral Abstracts (Abstracts 1-299)

(2018)   HEPATOLOGY

Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System

(2018) E C Goode et al.   HEPATOLOGY

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial

(2018) Gideon M. Hirschfield et al.   JOURNAL OF HEPATOLOGY

Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline

(2017) Lars Aabakken et al.   ENDOSCOPY

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis

(2017) Tobias J. Weismüller et al.   GASTROENTEROLOGY

A novel prognostic model for transplant-free survival in primary sclerosing cholangitis

(2017) Elisabeth M de Vries et al.   GUT

Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?

(2017) Steven P O’Hara et al.   GUT

Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner

(2017) Palak J Trivedi et al.   GUT

Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

(2017) Naoki Ikenaga et al.   GUT

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study

(2017) Elisabeth M. G. de Vries et al.   HEPATOLOGY

New therapeutic concepts in bile acid transport and signaling for management of cholestasis

(2017) Michael Trauner et al.   HEPATOLOGY

Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection

(2017) Kristine Cannon et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis

(2017) David N. Assis et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan

(2017) Atsushi Tanaka et al.   Journal of Hepato-Biliary-Pancreatic Sciences

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

(2017) Gideon M. Hirschfield et al.   JOURNAL OF HEPATOLOGY

nor Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

(2017) Peter Fickert et al.   JOURNAL OF HEPATOLOGY

Primary sclerosing cholangitis – a comprehensive review

(2017) Tom H. Karlsen et al.   JOURNAL OF HEPATOLOGY

Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis

(2017) Mette Vesterhus et al.   JOURNAL OF HEPATOLOGY

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

(2017) David C. Tully et al.   JOURNAL OF MEDICINAL CHEMISTRY

Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study

(2017) Elisabeth M.G. de Vries et al.   LIVER INTERNATIONAL

Genetics of primary sclerosing cholangitis and pathophysiological implications

(2017) Xiaojun Jiang et al.   Nature Reviews Gastroenterology & Hepatology

The Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts

(2017) Johannes Hov et al.   SEMINARS IN LIVER DISEASE

Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial

(2017) Ruth Bolier et al.   Trials

Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis

(2017) Mei Zhou et al.   Nature Communications

Primary sclerosing cholangitis: 50 years of a gut–liver relationship and still no love?

(2016) Tom H Karlsen   GUT

The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls

(2016) Martin Kummen et al.   GUT

Performance of magnetic resonance elastography in primary sclerosing cholangitis

(2016) John E Eaton et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study

(2016)   Journal of Gastrointestinal and Liver Diseases

Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis

(2016) Anna Baghdasaryan et al.   JOURNAL OF HEPATOLOGY

Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value

(2016) Elisabeth M. G. de Vries et al.   LIVER INTERNATIONAL

Evaluation of Biliary Calprotectin as a Biomarker in Primary Sclerosing Cholangitis

(2016) Annika Gauss et al.   MEDICINE

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

(2016) Sun-Gou Ji et al.   NATURE GENETICS

Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci

(2016) David Ellinghaus et al.   NATURE GENETICS

Primary Sclerosing Cholangitis

(2016) Konstantinos N. Lazaridis et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis

(2016) Natalia Gomez-Ospina et al.   Nature Communications

Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases

(2016) Ewa Wunsch et al.   Scientific Reports

Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis

(2016) Hanno Ehlken et al.   PLoS One

Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis

(2016) Malgorzata Milkiewicz et al.   Scientific Reports

Therapy of Primary Sclerosing Cholangitis - Today and Tomorrow

(2015) Emina Halilbasic et al.   DIGESTIVE DISEASES

Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice

(2015) Alexander G. Miethke et al.   HEPATOLOGY

Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis

(2015) Mette Vesterhus et al.   HEPATOLOGY

Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process

(2015) Cyriel Y. Ponsioen et al.   HEPATOLOGY

Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis

(2015) Suguru Mizuno et al.   Journal of Hepato-Biliary-Pancreatic Sciences

O080 : Early clinical features associated with long-term risk of transplantation in primary sclerosing cholangitis: Results from the UK-PSC consortium

(2015) E.C. Goode et al.   JOURNAL OF HEPATOLOGY

Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis

(2015) Elisabeth M.G. de Vries et al.   JOURNAL OF HEPATOLOGY

24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis

(2015) Martina Sombetzki et al.   JOURNAL OF HEPATOLOGY

EASL Clinical Practice Guidelines: Autoimmune hepatitis

(2015)   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Liver transplantation in the Nordic countries – An intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982–2013

(2015) Bjarte Fosby et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells

(2015) Mohamed-Sami Trabelsi et al.   Nature Communications

The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics

(2015) Jason M. Ridlon et al.   Acta Pharmaceutica Sinica B

Tu1002 Fenofibrate Improves Alkaline Phosphatase in Primary Sclerosing Cholangitis

(2015) Adriana Dejman et al.   GASTROENTEROLOGY

Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis

(2014) C. Rupp et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Baseline Values and Changes in Liver Stiffness Measured by Transient Elastography Are Associated With Severity of Fibrosis and Outcomes of Patients With Primary Sclerosing Cholangitis

(2014) Christophe Corpechot et al.   GASTROENTEROLOGY

Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis

(2014) Lauren N Bell et al.   LIVER INTERNATIONAL

Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review

(2014) Bogna Grygiel-Górniak   Nutrition Journal

Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis

(2013) T. H. Karlsen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study

(2013) J. H. Tabibian et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Minocycline: far beyond an antibiotic

(2013) N Garrido-Mesa et al.   BRITISH JOURNAL OF PHARMACOLOGY

Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist

(2013) Sama I. Sayin et al.   Cell Metabolism

Association Between Reduced Levels of Alkaline Phosphatase and Survival Times of Patients With Primary Sclerosing Cholangitis

(2013) Lina Lindström et al.   Clinical Gastroenterology and Hepatology

Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases

(2013) Emina Halilbasic et al.   Clinics in Liver Disease

Mucosal Addressin Cell Adhesion Molecule (MAdCAM-1) Expression Is Upregulated in the Cirrhotic Liver and Immunolocalises to the Peribiliary Plexus and Lymphoid Aggregates

(2013) Aftab Ala et al.   DIGESTIVE DISEASES AND SCIENCES

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis

(2013) Kirsten Boonstra et al.   HEPATOLOGY

Radiologic course of primary sclerosing cholangitis: Assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression

(2013) Ana Ruiz et al.   HEPATOLOGY

Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion

(2013) Nisanne S. Ghonem et al.   HEPATOLOGY

Mucosal immunity in liver autoimmunity: A comprehensive review

(2013) Palak J. Trivedi et al.   JOURNAL OF AUTOIMMUNITY

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis

(2013) Jimmy Z Liu et al.   NATURE GENETICS

Bile acid receptors as targets for drug development

(2013) Frank G. Schaap et al.   Nature Reviews Gastroenterology & Hepatology

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology

(2013) Ingmar Mederacke et al.   Nature Communications

Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis

(2013) James H. Tabibian et al.   Biomed Research International

High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia

(2012) L. Lindström et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

(2012) Akira Honda et al.   HEPATOLOGY

Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci atGPR35andTCF4

(2012) David Ellinghaus et al.   HEPATOLOGY

Immunomodulatory Effect of Vancomycin on Treg in Pediatric Inflammatory Bowel Disease and Primary Sclerosing Cholangitis

(2012) David N. Abarbanel et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci

(2012) Trine Folseraas et al.   JOURNAL OF HEPATOLOGY

Improvement of serum alkaline phosphatase to

(2012) Said Al Mamari et al.   JOURNAL OF HEPATOLOGY

Recurrence and rejection in liver transplantation for primary sclerosing cholangitis

(2012) Bjarte Fosby   WORLD JOURNAL OF GASTROENTEROLOGY

Urosdeoxycholic acid in primary sclerosing cholangitis: A meta-analysis and systematic review

(2012) Mohamed O. Othman et al.   Arab Journal of Gastroenterology

Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis

(2011) C. K. Triantos et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

(2011) M. H. Imam et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis

(2011) John E Eaton et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis

(2011) Peter P. Stanich et al.   DIGESTIVE AND LIVER DISEASE

What an endoscopist should know about immunoglobulin-G4-associated disease of the pancreas and biliary tree

(2011) L. Maillette de Buy Wenniger et al.   ENDOSCOPY

FXR activation inhibits inflammation and preserves the intestinal barrier in IBD

(2011) M. E. Wildenberg et al.   GUT

A biliary HCO3−umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes

(2011) Simon Hohenester et al.   HEPATOLOGY

Update on primary sclerosing cholangitis

(2010) Tom H. Karlsen et al.   DIGESTIVE AND LIVER DISEASE

Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis

(2010) N. Beraza et al.   GUT

Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells

(2010) Hongwei He et al.   HEPATOLOGY

Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression

(2010) Emmanouil Sinakos et al.   HEPATOLOGY

Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity

(2010) Evaggelia Liaskou et al.   HEPATOLOGY

Bezafibrate for the treatment of primary sclerosing cholangitis

(2010) Suguru Mizuno et al.   JOURNAL OF GASTROENTEROLOGY

Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue

(2010) Kirsten Muri Boberg et al.   JOURNAL OF HEPATOLOGY

Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms

(2010) Shi-Ying Cai et al.   JOURNAL OF LIPID RESEARCH

Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci

(2010) Espen Melum et al.   NATURE GENETICS

Genome-Wide Association Analysis in Primary Sclerosing Cholangitis

(2009) Tom H. Karlsen et al.   GASTROENTEROLOGY

p-ANCAs in autoimmune liver disorders recognise human  -tubulin isotype 5 and cross-react with microbial protein FtsZ

(2009) B. Terjung et al.   GUT

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice

(2009) Emina Halilbasic et al.   HEPATOLOGY

Portal fibroblasts: Underappreciated mediators of biliary fibrosis

(2009) Jonathan A. Dranoff et al.   HEPATOLOGY

Diagnosis and management of primary sclerosing cholangitis

(2009) Roger Chapman et al.   HEPATOLOGY

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

(2009) Keith D. Lindor et al.   HEPATOLOGY

EASL Clinical Practice Guidelines: Management of cholestatic liver diseases

(2009)   JOURNAL OF HEPATOLOGY

Long-term Treatment of Primary Sclerosing Cholangitis in Children With Oral Vancomycin: An Immunomodulating Antibiotic

(2009) Yinka K Davies et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Minocycline in the Treatment of Patients With Primary Sclerosing Cholangitis: Results of a Pilot Study

(2008) Marina G Silveira et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study

(2008) Frank P. Vleggaar et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

A Double-blind, Placebo-controlled, Randomized Study of Infliximab in Primary Sclerosing Cholangitis

(2008) Daan W. Hommes et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

(2008) Marina G. Silveira et al.   JOURNAL OF HEPATOLOGY